Conversation with Industry Leaders: Professor Alan Boyd By Dr Stephanie-Jayne Jones Continuing my series of conversations with leaders in our industry, I caught up with Professor Alan Boyd before Easter. Some of you will know him as the former President of the Faculty...
Understanding Gaucher disease By Bethany Bridge Gaucher disease is a rare genetic disorder caused by a mutation in the GBA1 gene and a subsequent deficiency in the enzyme glucocerebrosidase, which is responsible for breaking down the fat glucosylceramide into glucose...
The MHRA’s Patient Involvement Strategy 2021-25 By Hannah Kerfoot Following the Cumberlege review, published in 2020, the MHRA launched their Patient Involvement Strategy 2021-25. Now, in its final year, Pharmora is taking a look at what has been accomplished and what...
The EMA’s IRIS platform – what is it, and what does it mean for MAHs? By Hannah Kerfoot What is IRIS? Like its Ancient Greek mythologic namesake, Iris the messenger of the Gods, the IRIS platform has been developed by the European Medicines Agency (EMA) to ensure...
Recent trends in the pharmaceutical industry: Patient-focus By Hannah Kerfoot When attending conferences and conventions in the pharmaceutical industry in the past few years, you might have noticed, as we at Pharmora have, a shift in priorities. Patient-focus has been...
Landscape of Sarcoma Treatments Development By Swetha Babu Raising awareness about sarcoma is crucial due to its rarity and the challenges associated with its diagnosis and treatment, so we at Pharmora have decided to put together a blog detailing what Sarcoma is, and...
